UK private health services: half the £36bn is Bupa — and the margin tells you who's paying

888 UK health-services companies publish a full profit-and-loss, booking £36.3bn of combined turnover — and half of that is one company. Bupa, a global insurance and care group that consolidates its worldwide operations into a single UK entity, books £17.95bn on its own. What’s left is not a market but a shelf: the place where everything in UK health that isn’t a hospital, a GP surgery or a dentist ends up — care homes, foreign medtech sales arms, NHS spinouts, medico-legal firms, digital clinics, and roughly one name in five that is actually a charity. Sorted by what the companies really do, the economics snap into focus: the NHS spinouts run at a 0.3% median margin because they’re built to, the commercial tiers cluster in single digits, and the genuinely rich seam is a quiet set of business-to-business specialists — drug-safety outsourcing, teleradiology, waiting-list insourcing, workplace mental health — earning 10–30%. Figures are approximate — verify against a company’s own accounts before relying on any single number.

A catch-all, not a market

Three things change how you read every number below, so they come first.

• This is the “everything else” shelf of UK health. The private hospital groups (HCA, Spire, Circle, Ramsay), GP practices and dentists sit in neighbouring categories and are not here. Anyone quoting this £36bn as “the UK private health market” is wrong in both directions — it includes a global insurer’s worldwide revenue and excludes the actual private hospitals.
• A large slice isn’t selling healthcare at all. Around a fifth of the names are charities and foundations — the British Heart Foundation, Médecins Sans Frontières UK, Anthony Nolan — whose “turnover” is mostly donations, and whose margins mean nothing. A further tier is the UK sales arms of global device and pharma groups (Stryker, Cochlear, B. Braun, Abbott), whose UK margins are set as much by intra-group pricing as by any UK market.
• Group structures double-count. Several operators appear as two or three entities (a payroll company plus an operating company, a holdco consolidating an opco), and some subsidiaries file their own accounts alongside their group’s — Premex sits inside Examworks’ consolidation, Richmond Villages inside Bupa’s. Where we spotted a pure duplicate we removed it; treat any sum here as directionally right, not additive to the pound.

The giants

Only two companies here clear £1bn, and neither is what the category label suggests. Bupa is an insurer first, consolidating global health-insurance and care operations — we exclude it from every competitive read below. Nuffield Health is Britain’s biggest healthcare charity by trading revenue — a national network of private hospitals and fitness clubs — and it lost £36.4M on £1.45bn while growing revenue 7%: a not-for-profit running like one.

…and 878 more.

*Bupa’s FY2025 statutory income statement totals £18.2bn (£13.1bn of insurance revenue plus £5.1bn of non-insurance revenue); the £17.95bn here is the headline revenue measure in our dataset. Profit and growth are as published.

**Nuffield’s £36.4M is its published deficit after tax (2023: £64.0M) — the charity reports its bottom line post-tax rather than a headline pre-tax figure.

The first company that actually matches the label is Barchester — a care-home giant sitting under the health-services label — profitable and growing 11%. The most interesting giant is the loss-maker: Examworks UK, the medico-legal and accident-management consolidator that assesses injury claims for insurers and lawyers, lost £25M while adding staff (+27%) and five bolt-on acquisitions in a single year — buying market share in the most literal sense. The telling contrast sits inside its own group: its Bolton-based subsidiary Premex — acquired in 2019, its £151M already consolidated inside Examworks’ £331.7M — makes a comfortable 10% on the medico-legal core, while the group line is dragged into the red by the amortisation of acquisition goodwill (roughly £28M in the latest year). Two of the ten are Practice Plus Group entities — the private-equity-backed operator of NHS-contracted surgical hospitals and prison healthcare, nearly £500M combined and growing fast on exactly the work the NHS is outsourcing hardest.

The margin tells you who’s paying

Blend all 888 companies and the “average margin” is meaningless — the category mixes at least four revenue models. Split it, and each segment’s margin tells you who the customer is.

• NHS & public-sector spinouts: 0.3% median. The community-health providers spun out of the NHS in the early 2010s — Sirona Care & Health (£229.1M turnover, £168k profit), Bromley Healthcare, Medway Community Healthcare — are community-interest companies that exist to break even. A 0.1% margin here isn’t failure; it’s the constitution. Never benchmark a commercial operator against them, or them against anyone.
• Care operators: 4.5% median. Labour-heavy, fee-capped, wage-inflated. Barchester’s 5% is the segment in miniature.
• Medtech & pharma UK arms: 8.1% median. These margins are accounting outcomes — where a global group chooses to book UK profit — not competitive performance. WS Audiology’s 40% and Stryker’s 3% say more about group structure than about hearing aids or hip implants.
• B2B specialists: 7.2% median, but the widest spread. This is the segment where margin comes closest to reflecting the business — though several of its biggest names are group subsidiaries or listed plcs rather than independents, flagged in the table below — and the top of it is where the money is.

Where the money is: the B2B specialist tier

Filter to genuine mid-market operators (£5–100M turnover, profitable, ≥10% margin) and strip out the product arms, and a pattern emerges: almost nobody in this tier sells healthcare to patients. They sell a specialist service to an institution — a pharma company, an insurer, a hospital, an employer, a police force — on contracts that renew.

…plus a handful of harder-to-place operators at similar margins. Richmond Villages Operations (£65.4M of retirement villages at 12.2%) would make the cut on the numbers, but it is a Bupa subsidiary — already inside Bupa’s consolidation — so it is excluded here, per the rule above.

The headline margin belongs to PrimeVigilance — the UK contracting hub of Permira-owned Ergomed’s pharmacovigilance (drug-safety monitoring) arm — at 28.9% with just 57 staff. It is regulatory obligation turned into recurring revenue, but with most of the delivery cost bought in from sister companies, treat the margin as group structure as much as niche economics. The cleaner standout is Mountain Healthcare, which runs custody and sexual-assault-referral healthcare for police forces at 18.6% — a niche with statutory demand and almost no competitors. And note that selling to the NHS is not the same as being an NHS spinout: Medinet earns 15% insourcing waiting-list clinics into NHS hospitals — the deficit in elective capacity is, bluntly, its revenue model. The one consumer name, Optical Express, is high-ticket self-pay — closer to retail than to healthcare economics.

Growth, read with care

The fastest “growers” here are mostly not growth stories. Of the ten biggest year-on-year revenue jumps, three are charities (donations, not sales — a hospice posting a 47% “margin” is reporting fundraising, not trading), one is a property company collecting rent from its own group, and two are small pharma companies recognising licensing income.

The genuine signals are the ones backed by hiring. SWFT Clinical Services — an NHS-hospital-owned trading company — nearly tripled revenue to £57.8M with headcount up 182% to match. Practice Plus Group’s rehabilitation arm grew 20% with staff up 18% on prison-health contract wins. Kooth doubled to £66.7M at a 14.8% margin — impressive, but driven substantially by a single large overseas public-sector contract; concentration risk wearing a growth costume.

The shape and structure of the market

The small end of this category is unusually unprofitable — only 21–30% of the sub-£5M companies make money, against 65–74% once past £5M. That’s not a struggling industry; it’s the composition. The small tier is where the charities, the pre-revenue health-tech ventures and the part-time clinics live. The £5–25M band — 256 companies, two-thirds profitable — is the healthy operating heart of the category.

Headline concentration is extreme — the top five hold 58% — but the curve is a trompe-l’œil: the first company alone is half the money. Set Bupa aside and the remaining £18bn is one of the more fragmented corners of UK health: Nuffield holds about 8% of what’s left, Barchester 5%, nobody else reaches 3%, and 788 companies share the £5.9bn long tail. Ownership points the same way — about 62 companies carry a Holdings/Bidco/Topco-style name, the structural fingerprint of private-equity buyouts, and the buyers are working exactly the specialist tier above (Practice Plus and Examworks are both sponsor-owned). Fragmented, contract-based, statutory demand: this category is a roll-up factory.

What the map shows

1. Half the category is one insurer. Bupa’s £17.95bn consolidation dominates every total; no claim about “the UK private health market” survives without removing it first.
2. The label lies. Care homes, medtech sales arms, charities and medico-legal firms make up most of the money — the “clinic” you picture when you hear private health services is a minority of it.
3. The margin tells you who’s paying. NHS spinouts run at 0.3% by constitution; care fees support ~5%; the only margins that come close to reflecting competition are the B2B specialists’ — and even there, check who owns the entity first.
4. The money is B2B, not B2C. The double-digit tier sells drug-safety monitoring to pharma, teleradiology and insourcing to hospitals, mental health to employers, custody healthcare to police — institutional contracts, not patient volume.
5. NHS strain is the growth engine. The fastest genuine growers — waiting-list insourcing, prison health, trust trading companies — are all monetising the gap between NHS demand and NHS capacity.
6. It’s a roll-up factory. A fragmented mid-market of sticky-contract specialists with statutory demand is exactly what sponsors buy — and the holdco names show they already are.

Methodology and caveats

This covers the 888 UK companies in this corner of health services that publish a full profit-and-loss; thousands of smaller clinics and practices publish only abridged accounts and are invisible here, and the private hospital groups, GPs and dentists sit in neighbouring categories. Figures are each company’s latest filed accounts as of June 2026 — mostly financial years ending in 2024, with a few later year-ends (Bupa’s December 2025, Sirona’s March 2025). Segment labels are directional, assigned by reading what each of the 100 largest companies actually does. Group structures mean some operators appear more than once; one pure holdco duplicate was removed from the segment view, and one large hospice was excluded because its headline figure fails a basic plausibility check. Charity “turnover” is largely donation income and is never compared with trading revenue. Figures are approximate — verify against a company’s own accounts before relying on any single number. This is analysis, not financial advice; no company named here is known to be for sale, distressed beyond what its accounts state, or seeking investment.